Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.60 |
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | YAP1 | P46937 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483288 | 0.85 | PPARG (0.67) | CTSSCTSKITGB3ITGA2BYAP1 | |
| SCHEMBL9483283 | 0.85 | PPARG (0.67) | CTSSCTSKITGB3ITGA2BYAP1 | |
| SCHEMBL3131416 | 0.85 | ITGB3 (0.55) | CTSSCTSKITGB3ITGA2BITGAV | |
| SCHEMBL7538553 | 0.84 | YAP1 (0.51) | CTSSCTSKYAP1TSHRALDH1A1 | |
| SCHEMBL7538549 | 0.84 | YAP1 (0.51) | CTSSCTSKYAP1TSHRALDH1A1 | |
| SCHEMBL3135920 | 0.84 | CTSS (0.54) | CTSSCTSKITGB3ITGA2BITGAV | |
| SCHEMBL7326259 | 0.84 | YAP1 (0.53) | CTSSCTSKITGB3ITGA2BITGAV | |
| SCHEMBL3500200 | 0.84 | CACNA1B (0.56) | ITGB3ITGA2BYAP1ALDH1A1MEN1 | |
| SCHEMBL3500202 | 0.84 | CACNA1B (0.56) | ITGB3ITGA2BYAP1ALDH1A1MEN1 | |
| SCHEMBL7539252 | 0.83 | ALDH1A1 (0.50) | CTSSCTSKYAP1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | CTSS 330/4885CTSK 189/4885ITGB3 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.